6-MAPB

6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA.^[1][2][3][4] It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT_1B receptor agonist.^[5] The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives.^{[citation needed]} 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.^[6][7] It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.^[8]

6-MAPB

Clinical data
Other names	1-(Benzofuran-6-yl)-N-methylpropan-2-amine
Routes of administration	Oral
Drug class	Monoamine releasing agent; Serotonin 5-HT1B receptor agonist
Legal status
Legal status	CA: Schedule I DE: NpSG (Industrial and scientific use only) UK: Class B
Identifiers
IUPAC name 1-(Benzofuran-6-yl)-N-methylpropan-2-amine
CAS Number	1354631-79-0 Y
PubChem CID	122202866
ChemSpider	32078890
UNII	4J6PD2FN87
CompTox Dashboard (EPA)	DTXSID301010102
Chemical and physical data
Formula	C12H15NO
Molar mass	189.258 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(NC)CC1=CC(OC=C2)=C2C=C1
InChI InChI=1S/C12H15NO/c1-9(13-2)7-10-3-4-11-5-6-14-12(11)8-10/h3-6,8-9,13H,7H2,1-2H3 Key:QLAAURQYEAEHBO-UHFFFAOYSA-N

Interactions

See also: MDMA § Interactions, Trip killer § Antidotes of other hallucinogens, and MDMA/citalopram

See also

• Substituted benzofuran
• 5-MAPB, 5-APB, and 6-APB
• BK-5-MAPB and BK-6-MAPB
• TACT411 and TACT833